TYK2 kinase inhibitors - Pipeline Insight, 2024

This “TYK2 Kinase Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in TYK2 Kinase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

TYK2 Kinase Inhibitors Understanding

TYK2 Kinase Inhibitors: Overview

Tyrosine kinase 2 (Tyk2) is a non-receptor tyrosine-protein kinase, an enzyme that in humans is encoded by the TYK2 gene. Tyk2, together with three other family subtypes, namely, Jak1, Jak2, and Jak3, belong to the JAK family. This protein associates with the cytoplasmic domain of type I and type II cytokine receptors and promulgate cytokine signals by phosphorylating receptor subunits. It is also component of both the type I and type III interferon signaling pathways. Selective inhibition of Tyk2 can provide pharmacological benefits in the treatment of many diseases such as psoriasis, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), cancer, and diabetes.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence TYK2 Kinase Inhibitors R&D. The therapies under development are focused on novel approaches for TYK2 Kinase Inhibitors.

TYK2 Kinase Inhibitors Emerging Drugs Chapters

This segment of the TYK2 Kinase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TYK2 Kinase Inhibitors Emerging Drugs

Deucravacitinib: Bristol-Myers Squibb Deucravacitinib (formerly BMS 986165) is an orally available, selective allosteric inhibitor of tyrosine kinase 2 (Tyk2). Deucravacitinib is being studied in multiple immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus and inflammatory bowel disease. Bristol Myers Squibb is evaluating deucravacitinib in Phase 3 clinical studies inpsoriasis.

Brepocitinib: Pfizer Brepocitinib (PF-06700841) is a selective topical, tyrosine kinase 2 (TYK2) and janus kinase 1 (JAK1) inhibitor. The drug is in phase 2 clinical studies for the potential treatment of psoriasis and Atopic dermatitis in topical formulation and, in oral formulation for psoriatic arthritis, Crohn's disease, Ulcerative colitis, vitiligo, systemic lupus erythematosus, Alopecia areata and hidradenitissuppurativa.

TYK2 Kinase Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different TYK2 Kinase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on TYK2 Kinase Inhibitors

There are approx. 15+ key companies which are developing the TYK2 Kinase Inhibitors. The companies which have their TYK2 Kinase Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Bristol-Myers Squibb.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

TYK2 Kinase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TYK2 Kinase Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TYK2 Kinase Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TYK2 Kinase Inhibitors drugs.

TYK2 Kinase Inhibitors Report Insights

• TYK2 Kinase Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

TYK2 Kinase Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing TYK2 Kinase Inhibitors drugs?
• How many TYK2 Kinase Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for TYK2 Kinase Inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the TYK2 Kinase Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for TYK2 Kinase Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Incyte Corporation
• Bristol-Myers Squibb
• Oncostellae
• Pfizer
• Galapagos
• Haisco Pharmaceutical Group
• Sareum
• Oncostellae

Key Products

• Baricitinib
• Deucravacitinib
• OST-122
• Brepocitinib
• GLPG-3121
• FTP 637
• SDC-1801
• OST-246

This product will be delivered within 2 business days.